ロード中...
Idelalisib in a patient with refractory Waldenström’s macroglobulinemia complicated by anuric renal failure: a case report
BACKGROUND: Waldenström’s macroglobulinemia is a rare B-cell lymphoma. The gold standard treatment for Waldenström’s macroglobulinemia is an anti-CD20 antibody (rituximab) in combination with alkylating agents and dexamethasone. Treatment targeting the B-cell receptor such as ibrutinib (but not idel...
保存先:
| 出版年: | J Med Case Rep |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2018
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5996512/ https://ncbi.nlm.nih.gov/pubmed/29890999 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13256-018-1694-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|